486 related articles for article (PubMed ID: 33705648)
1. Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.
Seval GC; Topçuoğlu P; Demirer T
Turk J Med Sci; 2021 Dec; 51(6):2799-2809. PubMed ID: 33705648
[TBL] [Abstract][Full Text] [Related]
2. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
Di Ciaccio P; McCaughan G; Trotman J; Ho PJ; Cheah CY; Gangatharan S; Wight J; Ku M; Quach H; Gasiorowski R; Polizzotto MN; Prince HM; Mulligan S; Tam CS; Gregory G; Hapgood G; Spencer A; Dickinson M; Latimer M; Johnston A; Armytage T; Lee C; Cochrane T; Berkhahn L; Weinkove R; Doocey R; Harrison SJ; Webber N; Lee HP; Chapman S; Campbell BA; Gibbs SDJ; Hamad N
Intern Med J; 2020 Jun; 50(6):667-679. PubMed ID: 32415723
[TBL] [Abstract][Full Text] [Related]
3. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
Hu Y; Tan Su Yin E; Yang Y; Wu H; Wei G; Su J; Cui Q; Jin A; Yang L; Fu S; Zhou J; Qiu L; Zhang X; Liang A; Jing H; Li Y; Blaise D; Mohty M; Nagler A; Huang H
Curr Res Transl Med; 2020 Aug; 68(3):111-118. PubMed ID: 32620465
[TBL] [Abstract][Full Text] [Related]
4. The management of hematologic malignancies during the COVID-19 pandemic.
Hus I; Salomon-Perzyński A; Tomasiewicz K; Robak T
Expert Opin Pharmacother; 2021 Apr; 22(5):565-582. PubMed ID: 33342308
[No Abstract] [Full Text] [Related]
5. The impact of COVID-19 on patients with hematological malignancies: the mixed-method analysis of an Israeli national survey.
Levy I; Sharf G; Norman S; Tadmor T
Support Care Cancer; 2021 Dec; 29(12):7591-7599. PubMed ID: 34128108
[TBL] [Abstract][Full Text] [Related]
6. Managing patients with hematological malignancies during COVID-19 pandemic.
Sahu KK; Cerny J
Expert Rev Hematol; 2020 Aug; 13(8):787-793. PubMed ID: 32580592
[No Abstract] [Full Text] [Related]
7. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske C; Dreyling M; Alvarez-Larrán A; Apperley J; Arcaini L; Besson C; Bullinger L; Corradini P; Giovanni Della Porta M; Dimopoulos M; D'Sa S; Eich HT; Foà R; Ghia P; da Silva MG; Gribben J; Hajek R; Harrison C; Heuser M; Kiesewetter B; Kiladjian JJ; Kröger N; Moreau P; Passweg JR; Peyvandi F; Rea D; Ribera JM; Robak T; San-Miguel JF; Santini V; Sanz G; Sonneveld P; von Lilienfeld-Toal M; Wendtner C; Pentheroudakis G; Passamonti F
ESMO Open; 2022 Apr; 7(2):100403. PubMed ID: 35272130
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies.
Modemann F; Niederwieser C; Weisel K; Bokemeyer C; Fiedler W; Ghandili S
Leuk Lymphoma; 2022 Mar; 63(3):664-671. PubMed ID: 34668809
[TBL] [Abstract][Full Text] [Related]
9. Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.
Percival MM; Lynch RC; Halpern AB; Shadman M; Cassaday RD; Ujjani C; Shustov A; Tseng YD; Liu C; Pergam S; Libby EN; Scott BL; Smith SD; Green DJ; Gopal AK; Cowan AJ
JCO Oncol Pract; 2020 Sep; 16(9):571-578. PubMed ID: 32369409
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.
Goudsmit A; Cubilier E; Meert AP; Aftimos P; Stathopoulos K; Spilleboudt C; Loizidou A
Support Care Cancer; 2021 Nov; 29(11):6271-6278. PubMed ID: 33851236
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
Civriz Bozdağ S; Cengiz Seval G; Yönal Hindilerden İ; Hindilerden F; Andıç N; Baydar M; Aydın Kaynar L; Toprak SK; Göksoy HS; Balık Aydın B; Demirci U; Can F; Özkocaman V; Gündüz E; Güven ZT; Özkurt ZN; Demircioğlu S; Beksaç M; İnce İ; Yılmaz U; Eroğlu Küçükdiler H; Abishov E; Yavuz B; Ataş Ü; Mutlu YG; Baş V; Özkalemkaş F; Üsküdar Teke H; Gürsoy V; Çelik S; Çiftçiler R; Yağcı M; Topçuoğlu P; Çeneli Ö; Abbasov H; Selim C; Ar MC; Yücel OK; Sadri S; Albayrak C; Demir AM; Güler N; Keklik M; Terzi H; Doğan A; Yegin ZA; Kurt Yüksel M; Sadri S; Yavaşoğlu İ; Beköz HS; Aksu T; Maral S; Erol V; Kaynar L; İlhan O; Bolaman AZ; Sevindik ÖG; Akyay A; Özcan M; Gürman G; Ünal Ş; Yavuz Y; Diz Küçükkaya R; Özsan GH
Turk J Haematol; 2022 Feb; 39(1):43-54. PubMed ID: 34521187
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in hematological malignancies: Case series and literature review.
Ocheni S; Nwagha TU; Amu N; Obodo OI; Okereke K; Chikezie K; Ejezie CS; Ilechukwu GU; Obiatuegwu C
Ann Afr Med; 2023; 22(3):381-384. PubMed ID: 37417029
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.
Aumann S; Tsubary U; Nachmias B; Ben Yehuda D; Lavie D; Goldschmidt N; Vainstein V; Libster D; Saban R; Shaulov A; Israel S; Avni B; Grisariu S; Bdolah-Amram T; Gatt M; Zimran E
Eur J Haematol; 2023 Jul; 111(1):135-145. PubMed ID: 37096337
[TBL] [Abstract][Full Text] [Related]
14. Imaging of Hematological Patients in the Era of COVID-19.
Eshet Y; Avigdor A; Kedmi M; Tau N
Acta Haematol; 2022; 145(3):267-274. PubMed ID: 35100592
[TBL] [Abstract][Full Text] [Related]
15. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.
Yahalom J; Dabaja BS; Ricardi U; Ng A; Mikhaeel NG; Vogelius IR; Illidge T; Qi S; Wirth A; Specht L
Blood; 2020 May; 135(21):1829-1832. PubMed ID: 32275740
[TBL] [Abstract][Full Text] [Related]
16. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J; de la Cruz J; Cedillo Á; Llamas P; Duarte R; Jiménez-Yuste V; Hernández-Rivas JÁ; Gil-Manso R; Kwon M; Sánchez-Godoy P; Martínez-Barranco P; Colás-Lahuerta B; Herrera P; Benito-Parra L; Alegre A; Velasco A; Matilla A; Aláez-Usón MC; Martos-Martínez R; Martínez-Chamorro C; Susana-Quiroz K; Del Campo JF; de la Fuente A; Herráez R; Pascual A; Gómez E; Pérez-Oteyza J; Ruiz E; Alonso A; González-Medina J; Martín-Buitrago LN; Canales M; González-Gascón I; Vicente-Ayuso MC; Valenciano S; Roa MG; Monteliu PE; López-Jiménez J; Escobar CE; Ortiz-Martín J; Diez-Martin JL; Martinez-Lopez J;
J Hematol Oncol; 2020 Oct; 13(1):133. PubMed ID: 33032660
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
18. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.
Naimi A; Yashmi I; Jebeleh R; Imani Mofrad M; Azimian Abhar S; Jannesar Y; Heidary M; Pakzad R
J Clin Lab Anal; 2022 May; 36(5):e24387. PubMed ID: 35385130
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections.
Moreno-Sanchez F; Gomez-Gomez B
Curr Oncol Rep; 2022 Jul; 24(7):835-842. PubMed ID: 35316843
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
